281658-45-5

Upstream product

• 108-86-1 bromobenzene 
• 22244-22-0 ethyl 3,4-dihydro-2H-benzo [b][1,4]oxazine-2-carboxylate 
• 3674-13-3 2,3-dibromopropionic acid ethyl ester 
• 95-55-6 2-amino-phenol 
• 637-88-7 1,4-Cyclohexanedione 

Downstream Products

• 281658-41-1 toluene sulfonic acid 4-phenyl-3,4-dihydro-2H-benzo[1,4]oxazin-2-yl-methyl ester 
• 281658-40-0 (4-phenyl-3,4-dihydro-2H-benzo[1,4]oxazin-2-yl)-methanol 

Relevant academic research and scientific papers

BETA-SECRETASE MODULATORS AND METHODS OF USE

The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A, B, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.

Studies toward the discovery of the next generation of antidepressants. Part 5: 3,4-Dihydro-2H-benzo[1,4]oxazine derivatives with dual 5-HT1A receptor and serotonin transporter affinity

The design, synthesis, and structure-activity relationship of two novel classes of benzoxazine derivatives with dual selective serotonin reuptake inhibitors and 5-HT1A receptor activities are described.